Insilico Secures $115M in $2.75B Eli Lilly Deal
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Insilico Medicine signed a partnership deal with Eli Lilly earlier this week, receiving $115 million upfront.
- The deal includes up to $2.75 billion in total potential payments tied to milestone achievements.
- Insilico Medicine’s CEO discussed the company’s AI philosophy in the exclusive STAT+ article.
- STAT’s AI Prognosis newsletter, a subscriber‑only AI‑in‑health publication, hosts the article and requires a STAT+ subscription to unlock the full story.
- STAT+ provides a link to a separate story with additional details on the deal and Insilico’s background.
Why it matters: Insilico secures a $115 million cash infusion and the prospect of $2.75 billion in milestone payments, bolstering its R&D financing and accelerating its AI‑driven drug pipeline, while Eli Lilly gains a partner that can help expand its own drug discovery capabilities in the near term.
Ask SkimNews
